BC
Therapeutic Areas
Genus Pipeline
| Drug | Indication | Phase |
|---|---|---|
| PRRSSafe™ Pigs | Porcine Reproductive and Respiratory Syndrome (PRRS) Virus Resistance | R&D / Advanced Development |
| PIC Genetic Improvement Program | Commercial Pork Production (Feed Efficiency, Growth, Health) | Continuous Commercial Rollout |
| ABS Genetic Improvement Program | Dairy and Beef Production (Milk Yield, Fertility, Carcass Quality) | Continuous Commercial Rollout |
| Heat Tolerant Cattle Genetics | Improved Cattle Productivity in Warm Climates | R&D / Early Commercialization |
| Low Environmental Impact Genetics | Reduced Methane Emissions and Improved Nutrient Efficiency in Cattle | R&D / Trait Measurement |
Leadership Team at Genus
SW
Stephen Wilson
Chief Executive Officer (CEO)
AH
Alison Henriksen
Chief Financial Officer (CFO)
JM
J. Matthew (Matt) Ward
President, PIC (Pig Improvement Company)
NZ
Nate Zwald
Chief Operating Officer, ABS (American Breeders Service)
MT
Martin T. O’Malley
Senior Vice President, General Counsel & Company Secretary
KB
Karim Bitar
Chairman of the Board
IF
Iain Ferguson
Senior Independent Non-Executive Director
VS
Victoria Spicer
Non-Executive Director
SF
Susan Farr
Non-Executive Director
DJ
Dr. Jonathan Lightner
Non-Executive Director